XENETIC BIOSCIENCES
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-08-01
- Employees
- 4
- Market Cap
- $6.3M
- Website
- http://www.xeneticbio.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
Phase 2
Terminated
- Conditions
- Endometrial Cancer
- Interventions
- Drug: progestin therapy
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Xenetic Biosciences, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03077698
- Locations
- 🇺🇸
Providence St. Joseph Medical Center - Gynecology, Burbank, California, United States
🇺🇸University of California - Irvine Healthcare, Irvine, California, United States
🇺🇸UCLA, Los Angeles, California, United States
News
No news found